Cholesterol

Lp(a) drug pelacarsen cut levels 78% but did not prevent heart attacks or strokes in a major trial

In the seven-year Lp(a) HORIZON trial, monthly pelacarsen injections lowered lipoprotein(a) by 78% in 8,323 heart patients but did not reduce heart attacks, strokes or deaths. An estimated 64 million Americans have high Lp(a), and researchers say testing is still worthwhile.